Inhaled Insulin: A Proof-of-Concept Study
Authors: William T. Cefalu
Journal: Annals of Internal Medicine (2001)

Letters1 May 2001Inhaled Insulin: A Proof-of-Concept StudyWilliam T. Cefalu, MDWilliam T. Cefalu, MDUniversity of Vermont College of Medicine; Burlington, VT 05401 (Cefalu)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-9_Part_1-200105010-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The editorial (1) about our article on insulin therapy (2) requires some clarification because information that answers many of the issues raised was not available to the editorialist.Ours was a proof-of-concept study. Half of the participants in this open-label, controlled study were randomly assigned to remain on their preexisting treatment. The study tested the hypothesis that a regimen containing inhaled human regular insulin as the rapid-acting formulation provided glucose control as good as that of a conventional insulin regimen in patients with type 2 diabetes currently receiving such a regimen. Given the preliminary, albeit interesting, nature ...Reference1. Nathan DM. Inhaled insulin for type 2 diabetes: solution or distraction? [Editorial]. Ann Intern Med. 2001;134:203-7. [PMID: 11177338] LinkGoogle Scholar2. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, et al . Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med. 2001;134:203-7. [PMID: 11177333] LinkGoogle Scholar3. Cefalu WT, Balagtas CC, Landschulz WH, Gelfand RA. Sustained efficacy and pulmonary safety of inhaled insulin during 2 years of outpatient therapy [Abstract]. Diabetologia. 2000;34 Suppl 1 A47. Google Scholar Author, Article, and Disclosure InformationAuthors: William T. Cefalu, MDAffiliations: University of Vermont College of Medicine; Burlington, VT 05401 (Cefalu) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoInhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus William T. Cefalu , Jay S. Skyler , Ione A. Kourides , William H. Landschulz , Cecile C. Balagtas , Shu-Lin Cheng , and Robert A. Gelfand , for the Inhaled Insulin Study Group*Inhaled Insulin for Type 2 Diabetes: Solution or Distraction? David M. Nathan Metrics Cited byPulmonary Delivery of BiopharmaceuticalsInhaled insulin in diabetes mellitusInhaled human insulin (Exubera ® ): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitusInhaled insulinThe Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous InsulinInhaled Insulin: ExuberaInhaled insulin: recent advances in the therapy of Type 1 and 2 diabetesAlternative routes of insulin deliveryInhaled insulin in diabetes mellitusAlternative Routes of Insulin DeliveryNovel Drug Delivery Systems for InsulinInsuline per inhalatie 1 May 2001Volume 134, Issue 9_Part_1Page: 795KeywordsGlucoseHemoglobinHypoglycemicsInsulinOropharynxPulmonary functionSafetySafety studiesType 2 diabetesWeight gain ePublished: 1 May 2001 Issue Published: 1 May 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...